International journal of molecular sciences
May 22, 2025
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options, and early detection remains challenging due to the lack of reliable non-invasive biomarkers. This study investigated plasma and urine circulating tumor deo...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
May 1, 2025
PURPOSE: Pancreatic ductal adenocarcinoma (PDAC), known for its high fatality rate, is often diagnosed in its advanced stages where surgical options are not viable. This highlights the critical need for innovative and effective early detection techni...
INTRODUCTION: About 25% of patients undergoing pancreaticoduodenectomy (PD) for right-sided pancreatic ductal adenocarcinoma (PDAC) die within 1 y of diagnosis. These patients carry all the risks of significant morbidity with no survival advantage wh...
BACKGROUND: Deep learning(DL) models can improve significantly discrimination of lymph node metastasis(LNM) of pancreatic ductal adenocarcinoma(PDAC), but have not been systematically assessed.
In this study, using RNA-Seq gene expression data and advanced machine learning techniques, we identified distinct gene expression profiles between male and female pancreatic ductal adenocarcinoma (PDAC) patients. Building on this insight, we develop...
International journal of radiation oncology, biology, physics
Apr 2, 2025
PURPOSE: Stereotactic magnetic resonance guided adaptive radiation therapy (SMART) is a new option for local treatment of unresectable pancreatic ductal adenocarcinoma, showing interesting survival and local control (LC) results. Despite this, some p...
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is difficult to detect early and highly aggressive, often leading to poor patient prognosis. Existing serum biomarkers like CA19-9 are limited in early diagnosis, failing to meet clinical needs. Mac...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers known to humans. However, not all patients fare equally poor survival, and a minority of patients even survives advanced disease for months or years. Thus, there is a clinical ...
BACKGROUND: The cytological diagnostic process of EUS-FNA smears is time-consuming and manpower-intensive, and the conclusion could be subjective and controversial. Moreover, the relative lack of cytopathologists has limited the widespread implementa...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.